Tel: 01789 267520

Latest News: Research

Biogen announces how long they intend to keep open UK EAP for SMA Type 1

13 July 2017 / Posted in: Research

They state that this will be for ‘the remainder of the year in the UK’ and that they will ‘re-evaluate the progress of the reimbursement progress and the EAP towards the end of 2017’.

Read full story

PTC Therapeutics Provide Preliminary Clinical Data on RG7916

11 July 2017 / Posted in: Research

PTC Therapeutics presented an update on their splice-modifying drug, RG7916, at the 2017 Cure SMA Conference in Orlando, USA.

Read full story

Discussion about access to nusinersen

06 July 2017 / Posted in: Research

The All Party Parliamentary Group (APPG) for Muscular Dystrophy will discuss access to nusinersen on Tuesday 18th July in the Houses of Parliament. SMA Support UK and families will be there.

Read full story

Announcing the successful outcome of the 9th SMA Europe Research call

06 July 2017 / Posted in: Research

Based on the recommendations received by its Scientific Advisory Board, SMA Europe have awarded a total of €357,800 towards 3 cutting-edge SMA research projects.

Read full story

Update from NHS England’s June 6th meeting about the SMA Type 1 EAP

05 July 2017 / Posted in: Research

Lead clinicians and centre service managers were called together. SMA Support UK was also present. Due to the election ‘purdah’ and the NHSE communications approval process no one at the meeting has been able to discuss what went on until now with the release of the meeting notes.

Read full story

Waiting for a Place on the UK Nusinersen Expanded Access Programme for SMA Type 1?

04 July 2017 / Posted in: Research

Please help progress access to the programme by letting SMA Support UK know about your child and where you live so that we can discuss the national picture with clinicians and NHS funding bodies.

Read full story

Biogen SMA Community Update re: nusinersen

03 July 2017 / Posted in: Research

This shares the information discussed on the SMA Europe call on June 9th – most of which we have already published but it is a useful summary of their position and what they are doing now.

Read full story

European Medicines Agency (EMA) report on Spinraza

27 June 2017 / Posted in: Research

You can now read the detailed science behind the European Commission decision to authorise the marketing of nusinersen in Europe. This includes full details of the various clinical trials there have been.

Read full story

AVXS-101 Gene Therapy Manufacturing Process Streamlined

22 June 2017 / Posted in: Research

AveXis has announced that the process to manufacture their gene therapy drug for SMA, AVXS-101, is now aligned with expectations of the US Food and Drug Administration (FDA).

Read full story

How long will the UK EAP for eligible children with SMA Type 1 be open?

16 June 2017 / Posted in: Research

Today, Biogen confirmed that the actual date of closure of the EAP for new children will be agreed on a country by country basis. We are asking for it to stay open as long as possible in the UK and for the earliest possible advice as to when this closure date will be.

Read full story